{"name":"Accutar Biotechnology Inc","slug":"accutar-biotechnology-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AC676","genericName":"AC676","slug":"ac676","indication":"Other","status":"phase_1"},{"name":"AC699","genericName":"AC699","slug":"ac699","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AC676","genericName":"AC676","slug":"ac676","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC699","genericName":"AC699","slug":"ac699","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNR2VzcVJEN1NiSXh3WHR2Zi1GeHVOa252YnJqcWVjTEkyUWJiSWdHR1N2UlhTX3ZDZGRjRktMYkJqT3pUU3dVMzIydGhUOURkb0xYMGlEcGtobk1MLWtKSFlub043RXJuWmZRakVnRmhXMVM1TjBVRVRnYVBqNFdWaTJrNVZtUTBBSVhGcm5MUG0?oc=5","date":"2026-01-20","type":"pipeline","source":"PharmTech.com","summary":"Proteasomes: A Novel Approach to Target the Immune System - PharmTech.com","headline":"Proteasomes: A Novel Approach to Target the Immune System","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQTlYaEZqN3JLelZ3dHFJaEZTbDZMdVFXQWxvdThGbl9PMk1EZmlGcUl0ZnlQTnF2ZDlYN2xsMmdmcDFPaEhsNFVPSWZhRVB3aDF6MVBXY1d5RmJwT0ozWi1DMkJMYU1UTXRoV2FBaWpib25tZ29tR3NXUXN4TVp0ZFJIUW42RTZiQUl1US16N3UyUlQwNmZsUGhsYnpvYjh4ZEdkLTZlckpiOVhjZmxYSnRtOHhVTWFRdVJmWWZMUWxYOGVJVlJxX2R2dUZJRUQ3SHhNMA?oc=5","date":"2025-12-01","type":"pipeline","source":"The ASCO Post","summary":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups - The ASCO Post","headline":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQMTdDZTRxenpKSEN3SFppZFhmdW5DNGo5d0k1M2ZreUtpc0xYUGcxY1dQOXlmb2NDaklGY0RFU0tmZFF2NzlKUzFJaWhuOUJUellvRjBNR3pCVGZMbnItT3hWSVlGZUVSWXNmUHdURXhCVmZtWlhqQjNQU2VvRUI5blVOUkktQQ?oc=5","date":"2024-08-15","type":"pipeline","source":"Cure Today","summary":"AC699 Fast-Tracked for ESR1-Mutant Breast Cancer - Cure Today","headline":"AC699 Fast-Tracked for ESR1-Mutant Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPdnRTWXZsU3ZMdUgxY0Q2b3dEbEhrS1pXZmxJdVpqRktpQXpmSFFXY1JIemRhR0ZVVDNuRWtoX0ZyNlRpeDc3d1ZtdTFaTTV1bUI0aHlsenlkdjNxSzJjcXRrOHNGTi1Jdy1RaHJmUUpqcm1fVlpTa01PVDBJczlIVm1YNHl4ZWFHMU1mdVhMYVljczVVSUVUdkp2TTF0eUZCOXFQbnhhTktIeHZfa1NRbG9NSXI0RG1LRTBLRmpOSFlDN0hMR2hqU3AzVW12cnNUYnhyT1VTQ0xCRHlMZ2NJX205aUk?oc=5","date":"2024-08-14","type":"regulatory","source":"Business Wire","summary":"Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer - Business Wire","headline":"Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNdkROR21uSG1hdnZ1OUYyenVUSnlJTEZkZUptUENPVFNJOVk5Tmt4Z3Jyb0NPQmoxMElqOWFNUmF3Vl9hVU1zdGh6Xzl2dGtpeXFJRnRKdTVWRFd1Z2tpSkJlN29fVHljZ1J1Z2FyRmV6TE1tcVc5bG13a1VySlB1U2lFbk1SOWVoWEhfM2RWWmlwdW96UkRUM1h0RF9Qdl92NlN1aUMzTGVhUHJBaWlPYWdIdmYyaHJOcVNYOTAyajJVSWx6clAtMVpwaU9vd1R0dE84T1N3QmxfZ3RNLTBCdElCTm9HMkxnRVRyZ0o3RjJ3TUdVXzdIc3NTSjlGczM0U2F1R2RR?oc=5","date":"2024-08-12","type":"trial","source":"GlobeNewswire","summary":"PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire","headline":"PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQaGo0eHBiQzRUM2RSUk5vUzBtYkxEZkR3bjlVYnpXa0VLaWpMQkNyS1hOa3lBVFozQWNBc1NJRThLVFlOLXItSDJIbDlDYXR2UW9WeUVfdV9tc2N1QXEtWWEwYTNqZGpzeTRteFN2SVliajZEUG5lQVdDOWJkVWNiT1MtTUlNUWxzdzdScEVKZWdkeTJBVlJfcGtMVG55cUREaHVMam1Wa1pnZUZmMVVFZHhhRzFieVI3U0NQSHlUbXB0U0E3V1dJNWR4OA?oc=5","date":"2023-11-28","type":"deal","source":"PR Newswire","summary":"Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration - PR Newswire","headline":"Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQTkxfZ2F2NmpfMG9tQmV6bEFHWU5NbUc3UC11dVNmdEw0VlQzRFZISkx3ay1KMjh0S3JLeWhiOXpSb0RieGJtdDBWOXJhekZLYVJ6ME9oZ3VZOGRyUld1VDhHX182ZXZmQlRnajFwaUZmRURoUVZsN2xmUUVzeXlIYy1fY3AtbWxNRFNheS04YzBxMEFUNHhJQzgybGtCTkVtWjFUTExIOTdIMjFueFJUODFVbjdBYXI5T1lhelVRY1U5bVhrMEZ2b0NzaklaX2o5eHVfX3YxcjdzMGNyZ0RodTg5N2hycnduMlZHNTU0UkRCVk9PTnowZGNSakVUTW1FcGIwYXVzeEJUYzJOQWlyN3lMSGI3Rk1GX3R3ckln?oc=5","date":"2023-06-20","type":"trial","source":"Business Wire","summary":"Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies - Business Wire","headline":"Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNZE8yUmVBUkktcXY1RWhLeUc1aXl3QXU3eXo4Vml5cG9vVzZDcjJXVUhiendfand4cWI4WTJLTy0wX01Obnl6dXFzNGpHenAxamYwbG9FbnFGbEZBdUF5TkZzeW5lQWtTMGtqRHhfZjUyRm1ZSGJSSmdYbHd5Q3huNTZfRngzRllMdl9iWHNhUGZTOGpWcEt1Zkh0Q3JicnI1UUlPQlFZQnh0ZEFNOEtYODV3YUk1NllqY1A2ZGVXbmNrRDZLS0RsdjJoOEVnV09teFl0d21IQlhWdElzcnB5a01BZk1XV0Z3ZngtU3ZPeVRsRmFhcEQ5dmlrekdJSVpycmc?oc=5","date":"2023-02-03","type":"regulatory","source":"Business Wire","summary":"Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies - Business Wire","headline":"Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQRW5UeklaRDdmQ1VyTjg5UEY0UDFKR0ZQWVpIeEp0My0zUzFxd2ZtRjEzdjB0VjE4ZHNja2IzMG1CcFNVU21CaHRsYjVFZFNtUW5PYUM3RWttbmF6YXByYjQtT3l6TzNpejRITjZFUGo2TXhJVnl3YjVHbHZ3alZ4UTI0UVVDZ09mZms5enE0bV9mTk1DYlRRWU9ma1FjemRzRlRqSnh6N1p1cjdWdUtKZzJlVExNN2Zfa2cyNmVvRlB0bFhBUkhYMk85WG9zcnFGazVrWDJjQ2k0LVc3TFdvS25yckVBejhVVGI2SG05RmhyTDdGT0ZTUVpKQWZORzRteGs2MUZfYjdNQQ?oc=5","date":"2021-09-21","type":"regulatory","source":"Business Wire","summary":"Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0682 in ER-Positive Breast Cancer - Business Wire","headline":"Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0682 in ER-Positive Breast Cance","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}